Long-term benefits of hematopoietic stem cell-based macrophage/microglia delivery of GDNF to the CNS in a mouse model of Parkinson’s disease - Ge, Guo; Sivasubramanian, Barath P.; Geng, Bill D.; Zhao, Shujie; Zhou, Qing; Huang, Gang; O’Connor, Jason C.; Clark, Robert A.; Li, Senlin (Gene therapy, 2024)
Keywords: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 13; 13/51; 42/100; 42/109; 42/44; 631/378/1934; 64; 64/60; 692/699/375; Animal models; Animals; Biomarkers; Biomedical and Life Sciences; Biomedicine; Cell Biology; Cerebellum; Clinical outcomes; Clinical trials; Disease Models, Animal; Dopamine; Dopamine receptors; Dopaminergic Neurons - metabolism; Exosomes; Exosomes - metabolism; Food intake; Gene Expression; Gene Therapy; Gene transfer; Genetic Therapy - methods; Glial cell line-derived neurotrophic factor; Glial Cell Line-Derived Neurotrophic Factor - metabolism; Glial Cell Line-Derived Neurotrophic Factor - pharmacology; Glial Cell Line-Derived Neurotrophic Factor - therapeutic use; Glial cells; Hematopoietic Stem Cell Transplantation - methods; Hematopoietic stem cells; Hematopoietic Stem Cells - metabolism; Human Genetics; Macrophages; Macrophages - drug effects; Macrophages - metabolism; Male; Mice; Mice, Inbred C57BL; Microglia; Microglia - drug effects; Microglia - metabolism; Motor ability; Movement disorders; MPTP; Nanotechnology; Neostriatum; Neurodegeneration; Neurodegenerative diseases; Neuronal-glial interactions; Neurotrophic factors; Parkinson Disease - metabolism; Parkinson Disease - therapy; Parkinson's disease; Side effects; Stem cells; Substantia nigra; Substantia Nigra - metabolism